一个关于inclisiran用于治疗升高的LDL胆固醇的更新
Fotios Barkas1,2, Kausik Ray2
1Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Expert opinion on pharmacotherapy
|March 29, 2024
概括
英克利西兰是一种新的小干扰RNA,提供了一种精确有效的方法来降低低密度脂蛋白胆固醇,用于预防动脉样硬化心血管疾病. 这种疗法向蛋白转化酶亚素/素9型 (PCSK9) 具有降低全球ASCVD负担的潜力.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 在RNA治疗方面,RNA疗法.
背景情况:
- 动脉样性心血管疾病 (ASCVD) 仍然是全球领先的健康问题.
- 低密度脂蛋白胆固醇 (LDL-C) 的有效管理对于预防ASCVD至关重要.
- 需要新的治疗策略来解决ASCVD的持续负担.
研究的目的:
- 提供有关LDL-C管理在ASCVD预防中的作用的专家意见.
- 引入inclisiran,一种新型的小干扰RNA (siRNA),其向的蛋白转化酶是9型细素/素 (PCSK9).
- 根据临床试验数据,讨论inclisiran的机制,疗效和安全性.
主要方法:
- 审查inclisiran的作用机制,专注于肝脏细胞内PCSK9抑制.
- 与PCSK9单克隆抗体相比,对药理动力学和药理动力学特性进行分析.
- 从关键的III期研究 (ORION-9, -10, -11) 和现实世界的证据中评估临床试验数据.
主要成果:
- 英克利西兰表现出一种独特,精确的机制,具有很少的非目标效应.
- 临床试验显示inclisiran在降低LDL-C的有效性,作用时间延长.
- 聚合安全分析表明inclisiran.com的安全概况是有利的.
结论:
- 英克利西兰 (Inclisiran) 代表了降脂疗法的第一级突破.
- 它具有显著的潜力,可以减轻ASCVD的全球负担.
- 需要进一步的研究,包括儿科和心血管结局试验,以优化其使用.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
659
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
659
01:23Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137